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ABSTRACT
Patients with inflammatory bowel disease (IBD) are susceptible to
thromboembolism. Interestingly, IBD occurs less frequently in patients
with inherited bleeding disorders. Therefore, we analyzed whether F9-
deficiency is protective against the onset of acute colitis in a genetic
hemophilia B mouse model. In the 3.5% dextran sulfate sodium (DSS)-
inducedcolitismodel,F9-deficientmicewereprotected frombody-weight
loss and had a reduced disease activity score. We detected decreased
colonic myeloperoxidase activity and decreased CXCL1 levels in DSS-
treated F9-deficient mice compared with wild-type (WT) littermate
controls, indicating decreased neutrophil infiltration. Remarkably, we
identified expression of coagulation factor IX (FIX) protein in small
intestinal epithelial cells (MODE-K). In epithelial cell cultures, cellular FIX
protein expression was increased following stimulation with the bacterial
Toll-like receptor agonists lipopolysaccharide, macrophage-activating
lipopeptide-2 and Pam3CSK4. Thus, we revealed a protective role of
F9-deficiency in DSS-induced colitis and identified the intestinal
epithelium as a site of ectopic FIX.
This article has an associated First person interview with the first author
of the paper.
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INTRODUCTION
Inflammatory bowel diseases (IBD) including ulcerative colitis (UC)
and Crohn’s disease (CD) is a group of chronic, relapsing,
immunological, inflammatory disorders of the gastrointestinal tract
(Xavier and Podolsky, 2007).Microbiota-triggered Toll-like receptor
(TLR) signaling is protective in mouse models of inflammatory
bowel disease (IBD), but it is incompletely understood how gut
microbiota-derived TLR ligands regulate tissue protective factors of
the intestinal epithelium (Rakoff-Nahoum et al., 2004). CD and UC
are characterized by a dysbiotic gut microbiota (Frank et al., 2007).
Gut microbes control the development of IBD in the susceptible host
(Xavier and Podolsky, 2007). Interestingly, in genetic mouse models
with fecal transplantation of a colitogenic microbiota, the IBD
phenotype is transferrable into wild-type (WT) mice (Garrett et al.,
2010). Meanwhile, there are results from first clinical trials, testing
fecal microbiota transplantation as a new therapeutic option in IBD
(Mattner et al., 2016). Nevertheless, the pathogenesis of IBD remains
poorly understood.
Interestingly, IBDs occur less frequently than expected in patients
with inherited bleeding disorders (Thompson et al., 1995), but it is
currently unknown whether ectopically synthetized coagulation factors
in the intestine could be involved. Factor IX plasma levels were
found to be increased during IBD (Alkim et al., 2011). Deficiency of
coagulation factor IX (FIX) is the cause of hemophilia B, a severe
X-linked inherited bleeding disorder with a prevalence of 1:25,000
(Schulman and Smith, 1952; Rogers and Herzog, 2015). Factor IX
is efficiently activated via the binary complex of tissue factor with
activated coagulation factor VII (FVIIa) (Østerud and Rapaport, 1977)
and via the thrombin amplification loop by activated FXI (FXIa)
(Gailani and Broze, 1991). Activated FIX (FIXa) is a component of the
Xase complex (Ca2+/FVIIIa/FIXa), a key entity of the coagulation
pathway. TheXase complex promotes the cleavage of FX into activated
FXa and thus the generation of thrombin (Rogers and Herzog, 2015).
The generation of thrombin activity in the plasma of hemophilia B
patients is clearly dependent on FIX concentrations under stimulation
conditions with low tissue factor concentrations and, therefore, this
pathway was suggested to be relevant for pathophysiological thrombin
generation (Xi et al., 1989). To date, it is unresolved whether the
deficiency of FIX protects from the onset of colitis.
One pathway of how the coagulation system contributes to acute
intestinal mucositis is through activation of protease-activated
receptor (PAR) signaling (Borensztajn et al., 2009). This could be
triggered by epithelial sources of tissue factor (Luther et al., 1996)
and increased ectopic synthesis of clotting factors by the intestinal
epithelium (Yamada and Nagai, 1996). Enhanced coagulation
factor signaling via PAR1 was shown to depend on the commensal
gut microbiota (Reinhardt et al., 2012) and this signaling route has
been implicated in the pathogenesis of IBD (Danese et al., 2007). In
Crohn’s disease, hypercoagulability and platelet abnormalities with
a threefold higher risk for development of systemic thrombosis were
described (Sevenchenkova et al., 2015). During active IBD, blood
coagulation is activated due to tissue factor synthesis in monocytes
(Edwards et al., 1987) and tissue factor-dependent coagulation
activation was related to disease activity (Anthoni et al., 2007).
Therefore, we hypothesized that FIXa-dependent FXa generation
could aggravate the symptoms of IBD (Danese et al., 2007). It is
unknown whether FIX as a component of the Xase complex is
present in intestinal epithelial cells and if microbial-associated
molecular patterns (MAMPs) can induce the ectopic expression of
FIX. Here, we reveal in a dextran sulfate sodium (DSS) mouse
model of acute intestinal inflammation, that F9-deficiency isReceived 13 March 2018; Accepted 20 June 2018
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protective against colitis. Furthermore, we demonstrate with a
mouse-specific intestinal epithelial cell culture model that MAMP-
stimulation augments the ectopic intestinal synthesis of FIX.
RESULTS
F9-deficiency protects against DSS-induced colitis
As the prevalence of IBD was found to be reduced in hemophilic
patients (Thompson et al., 1995), wewere curious to explorewhether
coagulation factor IX-deficient (F9−/−) C57BL/6 mice (Lin et al.,
1997) are protected against 3.5% DSS-induced acute intestinal
inflammation. There was no difference in body-weight loss in the
untreated control groups (Fig. 1A), but strikingly, the body-weight
loss upon 3.5% DSS administration was significantly less in F9−/−
mice compared with WT littermate controls (Fig. 1B,C). The
reduced inflammation in DSS-treated F9−/− mice was further
corroborated by significantly longer colons and a reduced disease
activity index compared with DSS-treated WT controls (Fig. 1D,E).
These parameters did not differ in untreated mice (control).
To assess the degree of infiltration with neutrophils, we analyzed
the small intestinal and colon tissues of the DSS-treated mice.
Reduced myeloperoxidase (MPO) activity indicated decreased
neutrophil infiltration in the colon of F9−/− mice compared with
DSS-treatedWT controls (Fig. 1F).MPO activitywas also reduced in
the small intestine, but not in the liver and the spleen (data not shown).
Decreased neutrophil infiltration in F9−/−mice was also reflected by
reduced plasma CXCL1 levels, a chemokine promoting neutrophil
recruitment (Fig. 1G). Collectively, our results demonstrate that
F9-deficiency protects against DSS-induced colitis.
FIX protein levels in small intestinal epithelial cells are
increased by stimulation with TLR agonists
To investigate whether activation of TLRs can trigger FIX protein
expression in intestinal epithelial cells, we stimulated the
immortalized mouse intestinal epithelial cell line MODE-K (Vidal
et al., 1993) with the TLR4 agonist lipopolysaccharide (LPS), the
TLR2/6 agonist macrophage-activating lipopeptide-2 (MALP-2), or
the synthetic TLR2/1 agonist Pam3CSK4 for 2 and 4 h, respectively.
Immunoblot analyses showed that TLR2 stimulation, in particular,
increased epithelial FIX protein levels compared to unstimulated
controls, but also LPS increased epithelial FIX levels to some extent
(Fig. 2A,B). Our results demonstrate that TLR activation triggers
ectopic FIX expression in small intestinal epithelial cells.
Next, we investigated whether FIX protein is differentially
expressed in the distal small intestine of germ-free (GF) compared to
conventionally-raised (CONV-R) SwissWebster mice. Immunoblot
analyses of small intestinal tissue lysates and densitometric analysis
showed no differences in total small intestinal FIX protein levels
(Fig. 2C,D). Thus, the gut microbiota did not affect ectopic FIX
synthesis in the small intestine, suggesting that other mechanisms
may be involved.
DISCUSSION
Here, we used a F9-defecient hemophilia B mouse model to
induce acute colitis using DSS to gain insights into the mechanism
by which the coagulation pathway drives the inflammatory response to
experimental colitis. In support of epidemiologic data (Thompson
et al., 1995), our results demonstrated that the deficiency of FIX
reduced the extent of inflammation in DSS-induced colitis. To our
knowledge, we are the first to show that the anti-hemophilic clotting
factor IX is present in intestinal epithelial cells and F9-deficiency
rendered protection against colitis. We could show that TLR activation
augments FIX protein levels in murine intestinal epithelial cells.
FIX could be detected in small intestinal lysates, but its small intestinal
expression levels were not influenced by the gut microbiota.
Our study demonstrated ectopic expression of the zymogen FIX
in small intestinal epithelial cells. The finding that stimulation with
TLR2 and TLR4 agonists increased FIX protein levels in the
MODE-K cell culture model adds to the concept that the
coagulation system has evolved as a host defense system to
prevent invasion and spreading of microbes from the environment
(Levin and Bang, 1964; Massberg et al., 2010). Our finding on the
presence of FIX in the intestinal epithelium suggests that microbial
patterns might augment clotting reactions at inflammatory epithelial
interfaces.
In case of DSS-induced colitis, F9-deficiency reduces the extent
of the acute intestinal inflammation. In the 3.5% DSS-colitis mouse
model, F9-deficiency protected from weight loss and reduced colon
length. Moreover, the deficiency of this clotting factor diminished
the disease activity score. Reduced neutrophil infiltration into colon
tissue was associated with a marked reduction in plasma CXCL1
levels. Of note, our results are in line with other mouse colitis
models, showing that shifting the balance of anticoagulant pathways
to a procoagulant state aggravates colitis (Vetrano et al., 2011). The
correlation of an over-activation of the coagulation system in active
IBD is supported by a wealth of clinical data (Lee et al., 1968;
Boehme et al., 1997; Saibeni et al., 2010; Deutschmann et al., 2013;
Schmid et al., 2014). Importantly our study, applying the DSS-
model of acute intestinal inflammation on F9-deficient hemophilia
B mice, causally demonstrated that the FIX-dependent formation of
FXa in situ is most likely one of the factors that exacerbates the
symptoms of colitis. In conclusion, our findings support the extra
circulation source of coagulation factor IX and its expression is
increased in intestinal epithelial cells upon TLR stimulation. So far
little is known about the effects of direct oral anticoagulants on the
symptoms of active IBD. Future studies should focus on the role of
ectopic synthesis of coagulation factors in active IBD and
investigate the role of coagulation factor signaling in the
recruitment of inflammatory cells, its influence on epithelial
renewal and the regulation of intestinal barrier function.
MATERIALS AND METHODS
Mice
All mice were housed in a barrier facility (TARC, Translational Animal
Research Center, University Medical Center Mainz) under specific
pathogen-free (SPF) conditions with a 12 h light–dark cycle. They were
kept in EU Type II IVC cages with 2–5 mice per cage and given standard lab
diet (PMI LabDiet 5021, St. Louis, USA) and water ad libitum, in a 22°C
±2°C room. F9−/− mice (Lin et al., 1997) were originally purchased from
The Jackson Laboratory (Bar Harbor, USA) and the colony was maintained
by hemizygous breeding. Hence, the C57BL/6J WT control mice (F9+/+)
analyzed in this study were kept in the same cages as F9−/− mice also after
weaning. All mice used in the experiments were 8–16-week-old male and
female mice. All groups of mice were co-housed, and sex-, age- and weight-
matched. All mice used for experiments were free of clinical symptoms. All
procedures performed on mice were approved by the Animal Care and Use
Committee (ACUC; Landesuntersuchungsamt Rheinland-Pfalz, Koblenz,
Germany; 23 177-07/G 12-1-035).
DSS-induced colitis model and tissue preparation
Acute colitis was induced by providing 3.5% DSS solution (MW 36–50,000;
MP Biomedicals, Solon, USA) dissolved in autoclaved water for 7 days, with
daily consumptionmonitored for any strain specific reluctance. Themicewere
weighed and randomized into four groups. A normal control group comprising
WT (n=5), F9−/− (n=9) received autoclaved water without DSS orally for
7 days. A colitis group comprising WT (n=6) or F9−/− (n=8) received 3.5%
DSS in autoclaved tap water orally for 7 days. Mice were checked daily for
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their disease activity index. On day 7 the animals were euthanized by cervical
dislocation and organs including small intestine, liver and blood were
harvested, processed and stored at −80°C for further analysis. Colons were
excised upon autopsy and colon lengths were measured.
Evaluation of colitis
To reflect the general condition of mice, a disease activity index was
determined by an investigator, blinded to the protocol, by scoring the extent
of body-weight loss, stool guaiac positivity or gross bleeding, and stool
Fig. 1. F9−/− mice are protected during DSS-induced colitis. WT (F9+/+) and F9−/− mice were treated with 3.5% DSS in their drinking water for 7 days.
(A) Mice were weighed and compared to their day 0 weights set as 100% (untreated control); (n=5–9 mice). (B) Weight loss was measured daily during
treatment and is expressed as the average percentage of initial body weight±s.d; (n=6–8 mice). (C) Weight loss of the DSS-treated mice at day 7; average
percentage of initial body weight±s.d; (n=6–8 mice). (D) Control mice (untreated) (n=5–9) or DSS-treated mice (n=6–8) were euthanized on day 7, and
colons were removed and measured for their length. Results are expressed as the mean colon length±s.d. (E) Disease activity index was scored daily during
treatment. The median score is reported for each group of mice: control, n=5–9; treated group, n=6–8 mice per group. (F) Colonic myeloperoxidase (MPO)
activity in WT and F9−/− mice without (control) and with DSS administration was measured using absorbance values measured at 450 nm, n=4 mice per
group. (G) Plasma CXCL1 levels were determined in plasma samples of DSS-treated (n=4–5 mice) and untreated WT and F9−/− mice (n=5–8 mice).
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.
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consistency (Table 1) according to the method of Murthy et al. (Murthy
et al., 2002). Briefly, the mice were weighed before starting DSS
administration, during DSS treatment and on the day when the mice were
euthanized. Stool consistency and the degree of blood in stool were
evaluated every day until the end of the experiment using Haemoccult
(Beckman Coulter, Krefeld, Germany).
CXCL1 ELISA
CXCL1 concentrations were measured in murine plasma samples using an
ELISA kit according to the manufacturer’s protocol (R&D Systems,
Minneapolis, USA).
Myeloperoxidase activity assay
For myeloperoxidase (MPO) assay, organs were weighed, thoroughly
washed in PBS and stored at−80°C until analysis. Plasmawas collected and
stored at −80°C, and was diluted in PBS before the analysis. Tissues were
homogenized in in 0.5% hexadecyltrimethylammonium bromide (Sigma-
Aldrich; H6269) in 50 mM PBS, pH 6.0. Homogenates were freeze-thawed
thrice and centrifuged at 14,000 rpm at 4°C to remove the tissue debris.
Supernatant and plasma was used for the MPO assay. The MPO assay was
performed on clear supernatant and plasma in a 96-well plate by adding
1 mg/ml of dianisidine dihydrochloride (Sigma-Aldrich, D3252) and
0.00005% H2O2, optical density was measured at 450 nm. Human
neutrophil MPO (Sigma-Aldrich, M6908) was used as a standard (range:
0.5-0.015 U/ml). One unit of MPO activity is defined as the amount needed
to degrade 1.0 μmol of peroxide/min at 25°C.
Mouse intestinal epithelial cells
The murine small intestinal epithelial MODE-K cell line was kindly
provided by Dominique Kaiserlian (INSERM, Cedex, France) (Vidal et al.,
1993). MODE-K cells were maintained as described. MODE-K cells were
incubated with either vehicle or lipopolysaccharide (LPS, Escherichia coli
0111:B4; Sigma-Aldrich; 200 ng/ml), macrophage-activating lipopeptide-2
(MALP-2; Alexis, San Diego, USA; 2 μg/ml), Pam3CSK4 (InvivoGen, San
Diego, USA; 200 ng/ml) for 2 and 4 h at 37°C. Cells were then harvested for
further analysis.
Immunoblotting
To extract the proteins, MODE-K cells or harvested small intestines were
washed with PBS and homogenized in RIPA buffer containing 150 mM
NaCl, 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1% Triton X-100, 1%
sodium deoxycholic acid, 0.1% SDS, 5 mM phenylmethylsulfonyl fluoride
(PMSF), 10 µg/ml leupeptin and 20 µg/ml aprotinin with protease and
phosphatase inhibitor cocktail (Roche, Basel, Switzerland). The crude
extract was centrifuged at 10,000 g for 10 min at 4°C to remove cell debris.
The supernatant was used as protein source and frozen at−80°C until further
processing. The total protein was measured by Nanodrop (Thermo Fisher
Scientific). The total protein extracts were loaded on 8–10% SDS-PAGE
and separated by electrophoresis. The protein bands were transferred onto
PVDF membranes, which were blocked and incubated overnight with
primary antibodies; anti-factor IX (5 µg/ml, Acris, San Diego, USA) and
anti-Actin (1:1000, Sigma-Aldrich). Membranes were washed and
incubated with horseradish peroxidase-linked (HRP) secondary antibodies
(1:3000, Santa Cruz Biotechnology). Proteins were visualized by enhanced
chemiluminescence according to the manufacturer′s instructions (Cell
Signaling Technology). For densitometric analysis of protein bands, the
software ImageJ (NIH) was applied.
Statistical analysis
All values are expressed as the mean±s.d. Data sets were analyzed with
GraphPad Prism 6 (GraphPad) using one-way analysis of variance
(ANOVA) and paired t-tests. Differences of P<0.05 were considered
statistically significant.
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Fig. 2. Intestinal epithelial cell line responds with increased FIX
expression to TLR activation. (A) FIX immunoblot of vehicle treated or LPS
(100 ng/ml), MALP-2 (2 µg/ml) or Pam3CSK4 (500 ng/ml) stimulated
MODE-K cells for 2 and 4 h (n=3, representative blot). (B) Quantitative FIX
band density with respect to the actin loading control. (C) FIX immunoblot
analysis of small intestinal lysates of germ-free (GF) or conventionally-
raised (CONV-R) mice (representative immunoblot, n=6–7 mice).
(D) Corresponding FIX band density relative to the loading control actin band
density. *P<0.05; **P<0.01; ***P<0.001.
Table 1. Disease activity index
Score Weight loss (%) Stool consistency Occult/gross bleeding
0 None Normal Normal
1 1–5
2 5–10 Loose stools Guaiac
3 10–15
4 >15 Diarrhea Gross bleeding
The disease activity index (DAI)=(combined score of weight loss, stool
consistency, and bleeding)/3.
*Normal stools, well-formed pellets; loose stools, pasty stools that do not stick
to the anus; diarrhea, liquid stools that stick to the anus (Murthy et al., 2002).
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